Does anyone have information about the GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine?

While reading the current NCRN CLL clinical trials map I noticed an interesting addition in set up for CLL/SLL in supportive care alongside the many new trials. Does anyone know more about this particular vaccine?

“NCRN436: Safety, immunogenicity & efficacy of GSK Biologicals Herpes Zoster HZ/su candidate vaccine”

Shingles - live vaccines and the shingles vaccine is a popular topic as CLL/SLL patients are directed to avoid live vaccines. Herpes Zoster reaction is a common enemy for the CLL/SLL community especially during and after treatment.

Also at UK Trials Gateway:

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

Last edited by

2 Replies

  • The vaccine has been around since 2007 in various clinical trials as GSK1437173A


    The vaccine is based on QS-21...

    QS-21 Stimulon adjuvant has become a critical component in the development of investigational preventive vaccine formulations across a wide variety of infectious diseases, and appears to be essential for several investigational therapeutic vaccines intended to treat cancer and degenerative disorders. Currently, QS-21 is being studied in clinical trials in approximately 17 vaccine indications, of which four are in Phase 3 studies. These include RTS,S for malaria, MAGE-A3 for non-small cell lung cancer, MAGE-A3 for melanoma and Zoster Herpes for shingles. In addition, a QS-21-containing vaccine candidate is in Phase 2 trials for the treatment of Alzheimer’s disease. Agenus' licensees include GlaxoSmithKline and Janssen Alzheimer Immunotherapy**. QS-21 represents the most clinically advanced adjuvant.

  • Thanks Chris

    This is really interesting reading. A very useful plant extract. from creating soda suds to enhancing cancer vaccines.

    Thanks for pointing me to the GSK registry very useful. Is the ad


    Can you explain why this is the first exclusion?

    • Subject diagnosed with chronic lymphocytic leukaemia (CLL) who is receiving only oral cancer therapy (subject receiving intra-venous cancer therapy for CLL or intra-venous cancer therapy in combination with oral therapy may be enrolled).

You may also like...